Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Coherus BioSciences, Inc.

Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in Cancer

Release Date: August 30, 2019
Expiration Date: September 28, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in Cancer, consists of written content and video interviews of leading oncology experts featuring the use of biosimilars in the oncology setting. The video interviews address decision points and important questions commonly faced in the community practice setting.

Benefits of Participating

  • Understand the regulatory approval process for biosimilars
  • Interpret clinical data of biosimilars in relation to reference biological products
  • Know the most recent biosimilar approvals across cancer types
  • Consider approaches to monitor and identify adverse events related to biosimilars
  • Become more comfortable with integrating biosimilars into clinical practice and addressing patient concerns

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Coherus BioSciences, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video" will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists interested in the treatment of cancers using biosimilars. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients using biosimilars are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Recognize the comprehensive and stringent testing, extending from preclinical to clinical data, required to demonstrate the clinical comparability of biosimilars with reference drugs
  • Review clinical trial data in cancer that support the use of biosimilars across patient groups and integration of these agents into clinical practice
  • Address potential patient and clinician concerns regarding safety and efficacy in those who are incompletely informed about these agents
  • Outline pharmacovigilance considerations with biosimilars and ensure familiarity with the safety of both biosimilars and their corresponding reference products

Faculty, Staff, and Planners’ Disclosures


Bradley J. Monk
Bradley J. Monk, MD
Professor and Director
Division of Gynecologic Oncology
Creighton University School of Medicine at St. Joseph’s Hospital
University of Arizona College of Medicine
Medical Director
US Oncology, Gynecologic Oncology Research
Arizona Oncology (The US Oncology Network)
Phoenix, AZ

Disclosures: Grant/Research Support: Daiichi Sankyo, GlycoMimetics (clinical trial funding paid to university), ImmunoGen; Consultant: AbbVie, Advaxis, Agenus, Amgen, AstraZeneca, ChemoCare, ChemoID, Clovis, Conjupro, Eisai, Geistlich, Genmab, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson & Johnson, Mateon (formerly OXiGENE), Merck, Myriad, NuCana, OncoMed, OncoQuest, OncoSec, Perthera, Pfizer, Precision Oncology, Puma, Roche/Genentech, Samumed, Takeda, Tesaro, VBL; Speakers’ Bureau: AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, Tesaro.


Sanjiv S. Agarwala
Sanjiv S. Agarwala, MD
Professor of Medicine
Temple University
Philadelphia, PA
Chief, Oncology and Hematology
St. Luke’s Cancer Center (St. Luke’s University Health Network)
Bethlehem, PA

Disclosures: No relevant financial relationships with commercial interests.

Jeffrey Crawford
Jeffrey Crawford, MD
George Barth Geller Professor for Research in Cancer
Duke University Medical Center
Co-Director of the Solid Tumor Therapeutics Program
Duke Cancer Institute
Durham, NC

Disclosures: Grant Research Support: AstraZeneca, Genentech, Helsinn; Scientific Advisor: AstraZeneca, Coherus, Enzychem, G1 Therapeutics, Merck, Pfizer, Spectrum; Data and Safety Monitoring Board Member: BeyondSpring, Mylan, Roche.

Hope S. Rugo
Hope S. Rugo, MD
Professor of Medicine (Hematology/Oncology)
Director, Breast Oncology and Clinical Trials Education
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, CA

Disclosures: Grant/Research Support: Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi, Eisai, Seattle Genetics, MacroGenics, Immunomedics – All funding to University of California Regents; Travel Support: Daiichi, Mylan, Pfizer, Amgen, Merck, Puma.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By